Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction

• Autor(a) principal: Pereira, Manuel P.
• Data de Publicação: 2021
• Outros Autores: Zeidler, Claudia, Wallengren, Joanna, Halvorsen, Jon Anders, Weisshaar, Elke, Garcovich, Simone, Misery, Laurent, Brenaut, Emilie, Şavk, Ekin, Potekaev, Nikolay, Lvov, Andrey, Bobko, Svetlana, Szepietowski, Jacek C, Reich, Adam, Bozek, Agnieszka, Legat, Franz J, Metz, Martin, Streit, Markus, Serra-Baldrich, Esther, Gonçalo, Margarida, Storck, Michael, Nau, Teresa, Hoffmann, Vincent, Steinke, Sabine, Greiwe, Ina, Dugas, Martin, Augustin, Matthias, Ständer, Sonja
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10316/103521; https://doi.org/10.2340/00015555-3726
• topic: nodular prurigo; chronic nodular prurigo; patient-reported outcome; itch; pruritus;; therapy; Chronic Disease; Cross-Sectional Studies; Goals; Humans; Patient Satisfaction; Personal Satisfaction; Prurigo

Chronic nodular prurigo is characterized by recalcitrant itch. Patient perspectives on therapeutic goals, satisfaction with therapy and efficacy of therapeutic regimens for this condition are unknown. This questionnaire study examined these issues in 406 patients with chronic nodular prurigo from 15 European dermatological centres. Improvements in itch, skin lesions and sleep were the most important goals. Emollients, topical corticosteroids and antihistamines were the most frequently used treatments, while a minority of patients were prescribed potent medications, such as systemic immunosuppressants and gabapentinoids. Most patients were not satisfied with their previous therapy (56.8%), while 9.8% did not receive any therapy despite having active disease. A substantial number of respondents (28.7%) considered none of the therapeutic options effective. Although chronic nodular prurigo is a severe disease, most patients were not treated with potent systemic drugs, which may contribute to the high levels of dissatisfaction and disbelief in available therapies. Specific guidelines for chronic nodular prurigo and the development of novel therapies are necessary to improve care.